Y
Yusuke Ito
Researcher at Kyushu University
Publications - 11
Citations - 241
Yusuke Ito is an academic researcher from Kyushu University. The author has contributed to research in topics: Viral load & Nelfinavir. The author has an hindex of 5, co-authored 11 publications receiving 124 citations.
Papers
More filters
Journal ArticleDOI
Potential anti-COVID-19 agents, Cepharanthine and Nelfinavir, and their usage for combination treatment.
Hirofumi Ohashi,Hirofumi Ohashi,Koichi Watashi,Wakana Saso,Wakana Saso,Kaho Shionoya,Kaho Shionoya,Shoya Iwanami,Takatsugu Hirokawa,Takatsugu Hirokawa,Tsuyoshi Shirai,Shigehiko Kanaya,Yusuke Ito,Kwang Su Kim,Takao Nomura,Tateki Suzuki,Kazane Nishioka,Kazane Nishioka,Shuji Ando,Keisuke Ejima,Yoshiki Koizumi,Tomohiro Tanaka,Shin Aoki,Kouji Kuramochi,Tadaki Suzuki,Takao Hashiguchi,Katsumi Maenaka,Tetsuro Matano,Tetsuro Matano,Masamichi Muramatsu,Masayuki Saijo,Kazuyuki Aihara,Shingo Iwami,Makoto Takeda,Jane A. McKeating,Takaji Wakita +35 more
TL;DR: In this article, a panel of already approved drugs in a cell culture model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and identified two new agents having higher antiviral potentials than the drug candidates such as remdesivir and chroloquine in VeroE6/TMPRSS2 cells: the anti-inflammatory drug cepharanthine and human immunodeficiency virus protease inhibitor nelfinavir.
Posted ContentDOI
Multidrug treatment with nelfinavir and cepharanthine against COVID-19
Hirofumi Ohashi,Hirofumi Ohashi,Koichi Watashi,Wakana Saso,Wakana Saso,Kaho Shionoya,Kaho Shionoya,Shoya Iwanami,Takatsugu Hirokawa,Takatsugu Hirokawa,Tsuyoshi Shirai,Shigehiko Kanaya,Yusuke Ito,Kwang Su Kim,Kazane Nishioka,Kazane Nishioka,Shuji Ando,Keisuke Ejima,Yoshiki Koizumi,Tomohiro Tanaka,Shin Aoki,Kouji Kuramochi,Tadaki Suzuki,Katsumi Maenaka,Tetsuro Matano,Tetsuro Matano,Masamichi Muramatsu,Masayuki Saijo,Kazuyuki Aihara,Shingo Iwami,Makoto Takeda,Jane A. McKeating,Takaji Wakita +32 more
TL;DR: This study identifies a new multidrug combination treatment for COVID-19 that combines the HIV protease inhibitor Nelfinavir and the anti-inflammatory drug Cepharanthine to limit SARS-CoV-2 proliferation.
Posted ContentDOI
Modelling SARS-CoV-2 Dynamics: Implications for Therapy
Kwang Su Kim,Keisuke Ejima,Yusuke Ito,Shoya Iwanami,Hirofumi Ohashi,Yoshiki Koizumi,Yusuke Asai,Shinji Nakaoka,Koichi Watashi,Robin N Thompson,Shingo Iwami +10 more
TL;DR: It is indicated that therapies that block de novo infections or virus production are most likely to be effective if initiated before the peak viral load, but therapies that promote cytotoxicity are likely to have only limited effects.
Journal ArticleDOI
Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro
Kaho Shionoya,Kaho Shionoya,Masako Yamasaki,Masako Yamasaki,Shoya Iwanami,Shoya Iwanami,Yusuke Ito,Shuetsu Fukushi,Hirofumi Ohashi,Hirofumi Ohashi,Wakana Saso,Wakana Saso,Tomohiro Tanaka,Shin Aoki,Kouji Kuramochi,Shingo Iwami,Yoshimasa Takahashi,Tadaki Suzuki,Masamichi Muramatsu,Makoto Takeda,Takaji Wakita,Koichi Watashi +21 more
TL;DR: Mefloquine showed higher anti-SARS-CoV-2 activity than Hydroxychloroquine in VeroE6/TMPRSS2 and Calu-3 cells, with IC50 = 1.28 μM, IC90 = 2.31 μM and IC99 = 4.39 μM as discussed by the authors.
Posted ContentDOI
Inferring Timing of Infection Using Within-host SARS-CoV-2 Infection Dynamics Model: Are “Imported Cases” Truly Imported?
Keisuke Ejima,Kwang Su Kim,Yusuke Ito,Shoya Iwanami,Hirofumi Ohashi,Yoshiki Koizumi,Koichi Watashi,Ana I. Bento,Kazuyuki Aihara,Shingo Iwami +9 more
TL;DR: In an early phase of outbreak due to entrance or re-entrance of the virus to countries/communities, collecting viral load data over time from cases from symptom onset is highly recommended, because viral loadData are valuable to infer the timing of infection and distinguish between imported cases and ongoing local transmission.